A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study First FcRn blocker to demonstrate sustained ...

Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.

Applications are now open for submission at www.UCBMGSCHOLARSHIP.com The UCB U.S. Myasthenia Gravis Scholarship is open to eligible applicants who intend to pursue educational opportunities such ...

Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...